Achieving therapeutic vancomycin levels in pediatric patients

Area of Science:

• Pediatric Pharmacology
• Infectious Disease Management
• Antibiotic Dosing Optimization

Background:

• Vancomycin is a critical antibiotic for treating methicillin-resistant Staphylococcus aureus (MRSA) infections.
• Limited data exists for optimal vancomycin dosing and monitoring in pediatric populations.
• Clinicians often rely on adult guidelines for pediatric vancomycin administration.

Purpose of the Study:

• To determine the vancomycin doses needed to achieve therapeutic trough levels (10-20 mg/L) in pediatric patients.
• To evaluate the efficacy of current empiric vancomycin doses (40-60 mg/kg/day) in achieving these levels in children.
• To analyze dosing requirements across different pediatric age groups.

Main Methods:

• A retrospective chart review was conducted on pediatric patients (1 month to 18 years) receiving vancomycin.
• Demographic data, vancomycin dosage, and steady-state trough concentrations were analyzed.
• The study period spanned from November 2011 to October 2012 at a single institution.

Main Results:

• Only 39% of pediatric patients achieved therapeutic vancomycin trough levels with current empiric dosing.
• Mean daily doses required for therapeutic levels varied by age: 57.8 mg/kg (1-5 months), 68.9 mg/kg (6-23 months), 65.8 mg/kg (2-12 years), and 55.7 mg/kg (13-18 years).
• Higher doses than the standard 40-60 mg/kg/day were necessary for most pediatric age groups.

Conclusions:

• Standard empiric vancomycin dosing (40-60 mg/kg/day) is inadequate for achieving therapeutic trough levels in the majority of pediatric patients.
• The study suggests increased starting doses: 60 mg/kg/day for infants (1-5 months) and adolescents (13-18 years).
• A higher starting dose of 70 mg/kg/day is recommended for children aged 6 months to 12 years.